Laurion Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Laurion Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,939	Closed	-$932K	–	480
2022 Q1	$932K	Buy	+7,939	New	+$919K	0.01%	255
2021 Q3	–	Sell	-20,699	Closed	-$2.72M	–	684
2021 Q2	$2.72M	Buy	+20,699	New	+$2.76M	0.02%	341
2020 Q4	–	Sell	-6,500	Closed	-$1M	–	635
2020 Q3	$1M	Sell	6,500 -190	-3%	-$27.3K	0.01%	451
2020 Q2	$989K	Buy	+6,690	New	+$919K	0.01%	458
2020 Q1	–	Sell	-9,100	Closed	-$1.27M	–	747
2019 Q4	$1.27M	Buy	9,100 +5,078	+126%	+$564K	0.01%	529
2019 Q3	$387K	Sell	4,022 -12,210	-75%	-$1.36M	﹤0.01%	814
2019 Q2	$1.87M	Buy	+16,232	New	+$1.94M	0.02%	410
2018 Q1	–	Sell	-54,952	Closed	-$2.2M	–	1315
2017 Q4	$2.2M	Sell	54,952 -228,378	-81%	-$8.3M	0.01%	750
2017 Q3	$10.3M	Buy	+283,330	New	+$8.13M	0.05%	320
2017 Q1	–	Sell	-83,200	Closed	-$1.68M	–	1279
2016 Q4	$1.68M	Buy	+83,200	New	+$1.66M	0.02%	617

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Laurion Capital Management's ASND Position: Q2 2022 in Review

Laurion Capital Management sold out of Ascendis Pharma A/S (ASND) in Q2 2022, closing a stake of 7,939 shares — an estimated $932K sold.

Laurion Capital Management first reported a position in ASND in Q4 2016 and held it in 10 quarters. The position peaked at $10.3M in Q3 2017. 168 funds tracked by Wall St. Rank hold ASND as of Q2 2022.

Laurion Capital Management reported no remaining Ascendis Pharma A/S position as of Q2 2022 after selling out during the quarter.
Laurion Capital Management sold 7,939 Ascendis Pharma A/S shares in Q2 2022, an estimated $932K.
Laurion Capital Management first reported a position in Ascendis Pharma A/S in Q4 2016 and held it in 10 quarters.
Laurion Capital Management's Ascendis Pharma A/S position peaked at $10.3M in Q3 2017.
168 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.